Carisma Therapeutics, Inc.
CARM
$0.06
$0.019.62%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1,236.78% | -- | 9.77% | -14.83% | -11.55% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,236.78% | -- | 9.77% | -14.83% | -11.55% |
| Cost of Revenue | -98.26% | -84.16% | -47.57% | -19.76% | -42.07% |
| Gross Profit | 667.35% | 60.33% | 61.41% | 21.16% | 49.50% |
| SG&A Expenses | -76.19% | -39.68% | -28.25% | -46.34% | -21.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -91.31% | -72.31% | -42.97% | -27.04% | -36.84% |
| Operating Income | 433.34% | 50.49% | 52.16% | 29.38% | 41.17% |
| Income Before Tax | 452.05% | 12.44% | 51.18% | 16.64% | 40.65% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 452.05% | 12.44% | 51.18% | 15.86% | 40.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 452.05% | 12.44% | 51.18% | 15.86% | 40.65% |
| EBIT | 433.34% | 50.49% | 52.16% | 29.38% | 41.17% |
| EBITDA | 453.14% | 49.38% | 51.32% | 30.11% | 42.69% |
| EPS Basic | 450.39% | 12.95% | 52.16% | 18.60% | 42.52% |
| Normalized Basic EPS | 447.83% | 52.71% | 52.16% | 28.51% | 42.50% |
| EPS Diluted | 449.12% | 12.95% | 52.16% | 18.60% | 42.52% |
| Normalized Diluted EPS | 446.57% | 52.71% | 52.16% | 28.51% | 42.50% |
| Average Basic Shares Outstanding | 0.48% | 0.59% | 2.03% | 3.37% | 3.23% |
| Average Diluted Shares Outstanding | 0.85% | 0.59% | 2.03% | 3.37% | 3.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |